Transfusion strategies in women during Major Obstetric Haemorrhage
Recruiting
- Conditions
- Major Obstetric Haemorrhage
- Registration Number
- NL-OMON28409
- Lead Sponsor
- Center for Clinical Transfusion Research (Sanquin Leiden) and Leiden University Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1600
Inclusion Criteria
Transfusion of FFP and/or platelets alongside RBC transfusion
AND
Obstetric haemorrhage in pregnancy (including early pregnancy), during the first 24 hours following delivery or in puerperium (limited to 6 weeks after delivery).
Exclusion Criteria
Timing of transfusion of blood components not recorded or not obtainable.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Maternal mortality and severe maternal morbidity. Severe maternal morbidity will be defined as a postpartum hysterectomy, postpartum arterial embolisation and/or intensive care unit admission.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie coagulopathy in Major Obstetric Haemorrhage and how do transfusion strategies modulate them?
How does the transfusion ratio of plasma to red blood cells in NL-OMON28409 compare to standard-of-care protocols for MOH?
Which hemostatic biomarkers predict response to restrictive vs. liberal transfusion strategies in postpartum hemorrhage?
What adverse events are associated with fibrinogen concentrate use in MOH observational studies like NL-OMON28409?
How do antifibrinolytic agents like tranexamic acid complement transfusion strategies in managing MOH subtypes?